Health Canada has published 11 updated natural health product (NHP) monographs effective March 27, 2026, continuing its modernization of the monograph framework under the Natural Health Products Regulations.
The latest publication includes updates to the monographs for cayenne (oral), cayenne (topical), cranberry, dried cranberry juice, devil’s claw, European pennyroyal, horseradish, Roman chamomile, stinging nettle, stinging nettle juice, and high-dose vitamin D.
For licence holders, regulatory teams, and product development functions, these revisions should prompt a focused assessment of existing product licence conditions, recommended use or purpose statements, cautionary and risk language, dosage parameters, and finished label text to ensure both currently marketed products and future line extensions remain fully aligned with the updated monograph conditions of use.
About Health Canada Monographs and Monograph Updates
Health Canada NHP monographs are pre-cleared evidence documents that establish the acceptable conditions of use for specific medicinal ingredients or product categories under the Natural Health Products Regulations. They define the parameters that support monograph-based product licensing, including permitted recommended use or purpose statements, dosage ranges, routes of administration, duration of use limits, risk information, cautionary statements, and, where applicable, quality expectations.
When a product aligns fully with an applicable monograph, applicants may rely on Health Canada’s pre-assessed safety and efficacy framework instead of submitting a more extensive evidence package. This allows many product licence applications to move through the licensing pathway efficiently and with greater predictability.
Why Is Health Canada Introducing Monograph Updates?
Health Canada updates NHP monographs to ensure the compendium continues to reflect current scientific evidence, post-market safety findings, evolving risk thresholds, and stakeholder feedback.
These revisions are typically introduced when new adverse event data, updated scientific literature, international regulatory developments, or prior ingredient consultations support refinement of the existing conditions of use. Monograph updates allow Health Canada to standardize revised dosage limits, strengthen risk communication, clarify permitted claims, or introduce new ingredients into existing monograph frameworks.
What Are the Responsibilities of Product Licence Holders Following a Monograph Update?
For product licence holders, a monograph update creates an immediate post-licensing compliance obligation. The first step is a formal impact assessment against the revised monograph, comparing the updated conditions of use with the product’s authorized licence, formulation, claims framework, and current marketed label text. This assessment should confirm whether the revision affects the recommended use or purpose, dose, duration of use, cautionary and warning statements, contraindications, medicinal ingredient descriptions, or available bilingual label space.
Where a revised monograph introduces new safety language, such as a warning or risk statement, affected licence holders are expected to implement label updates within Health Canada’s established timelines. In safety-driven cases, this may include a post-licensing Information Request Notice (IRN) with accelerated implementation requirements.
Beyond the product label updates, licence holders should also assess existing finished goods inventory, determine whether over-labelling is feasible, plan reprint timing, and confirm whether a notification or amendment filing is required.
Compliance responsibilities also extend to marketplace listings, technical product sheets, distributor specifications, and downstream promotional claims, all of which should remain aligned with the revised monograph conditions to support ongoing licence compliance.
Updated Health Canada NHP Monographs Published March 27, 2026
For licence holders with products relying on the updated monographs for cayenne (oral), cayenne (topical), cranberry, dried cranberry juice, devil’s claw, European pennyroyal, horseradish, Roman chamomile, stinging nettle, stinging nettle juice, and high-dose vitamin D, the immediate next step is to cross-reference the revised monograph text against existing product licences and current marketed labels.
The focus should be on identifying any changes to conditions of use that may affect authorized claims, dosage directions, risk information, route-specific wording, or ingredient restrictions already reflected in the licence and finished packaging. This comparison should also consider whether any revised wording creates downstream packaging implications, particularly where bilingual space is already constrained.
Early review will help determine whether updates can be incorporated into the next label revision cycle or whether a more immediate compliance action is required.
Multi-Vitamin and Mineral (MVM) Monograph Update Delayed to April 2026
Health Canada has also notified stakeholders of the delayed update to the multi-vitamin/mineral (MVM) supplements monograph, which Health Canada now expects to publish at the end of April 2026.
Given the extensive use of this monograph across adult multivitamins, prenatal supplements, stress-support products, and B-complex combinations, the revised publication is expected to affect a large number of existing Canadian NHP licences.
Vitamin B6 Peripheral Neuropathy Warning at 10 mg or More
The delayed update to the multi-vitamin and mineral (MVM) monograph follows Health Canada’s Summary Safety Review published on March 11, 2026, which identified a possible link between vitamin B6-containing natural health products and peripheral neuropathy at daily doses of 10 mg or more.
As a result, the revised MVM monograph is expected to introduce updated risk statements describing the warning signs and symptoms of peripheral neuropathy, including numbness, tingling, and pain in the hands or feet. Health Canada has also indicated that affected products should include accompanying stop-use and healthcare professional consultation language.
Products Most Likely to Be Affected
This update is particularly relevant for product categories that commonly provide vitamin B6 at or above the 10 mg daily threshold, including daily multivitamins, prenatal formulas, stress-support products, energy blends, and B-complex supplements.
NMN Added to the Revised MVM Monograph
Health Canada also confirmed that nicotinamide mononucleotide (NMN) will be incorporated into the revised MVM monograph, following stakeholder feedback received during the 2024 consultation on the single-ingredient NMN monograph.
Why NMN Was Not Previously Included
NMN was initially introduced through a standalone monograph pathway, which allowed Health Canada to first establish the ingredient’s accepted conditions of use, including dose parameters, risk information, and permitted claims as a single medicinal ingredient. Once these foundational conditions were defined, Health Canada was better positioned to assess how NMN could fit within broader combination-product frameworks such as the MVM monograph.
What This Means for Future Formulations
The addition of NMN to the revised MVM monograph is intended to improve regulatory clarity for combination formulations that pair NMN with vitamins and minerals. In practice, this may reduce the need for more customized evidence strategies where the remainder of the formula already aligns with the existing MVM framework.
This update is particularly relevant for future formulations positioned in healthy aging, mitochondrial support, and longevity-focused nutritional innovation, as it may support a more efficient monograph-based licensing pathway for NMN-containing multivitamin and mineral products.
Final Remarks
Taken together, these March 2026 monograph updates and the forthcoming MVM revision reflect Health Canada’s continued effort to keep the NHP monograph framework aligned with current safety evidence, evolving ingredient innovation, and practical licensing needs.
For licence holders, the immediate priority is to complete a structured review of products relying on the newly updated monographs while also proactively assessing any multivitamin and mineral products that may be affected by the upcoming vitamin B6 warning language and NMN integration.
Early alignment between revised monograph conditions, existing licences, and marketed labels will help support smoother inventory transitions, reduce the risk of reactive label changes, and maintain ongoing compliance as the updated MVM monograph is published later this month.
NHP Consulting Services for Efficient Market Entry
Is your team seeking support with NHP licensing and monograph update implementation? SNI’s experts are here to help. Since 2004, we have supported over 1,000 industry leaders and emerging brands with successful Canadian market entry.
Our team provides end-to-end support across regulatory strategy, product and site licensing, monograph alignment, quality systems, label compliance, and post-market change management, helping brands navigate both initial submissions and ongoing NHP compliance obligations with confidence.
Connect with the SNI team to learn how we can help streamline market entry, accelerate licensing efficiency, and support compliant implementation of evolving Health Canada requirements.
⬇️ Send us a request to learn more about labelling solutions
✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
